NEW! RMJ has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.
Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.
The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.
Specific allergen immunotherapy results in children with asthma due to pollens allergy. Clinical study
Introduction. Specific allergen immunotherapy (STI) is the causal treatment of asthma. SIT gives a specific response to the changing LT response (deviation of the immune response), induction of anergy (decrease of LTh2), induces tolerance and modifies the inflammatory response. Pollen produces in our country seasonal allergic asthma in children and adults.
Materials and methods. Our study was conducted using grass pollen extracts and comprised a total of 47 children with asthma, allergic to pollens, aged 5-14. Administration was seasonal (November to April), oral (sublingual solutions). It was indicated in the treatment of children with asthma and rhinitis with definite diagnosis where eviction was not possible. There have been previously detailed history and a careful clinical examination, skin prick tests to pollens with intense response, more elevated IgE, and spirometry confirming bronchospasm. Grass pollen extracts with initial low doses were used, gradually increasing the amount and concentration, and a gradual decrease, at a total of 6 months per year, with a duration of three years.
Discussion. The evaluation was performed by clinical follow-up (symptom score and drug consumption), spirometry and by improving the quality of life assessment. There were no serious side effects during treatment.
Conclusion. SIT in children with pollens allergic asthma is the causal therapeutic method; treating asthmatic children over 3 years old; reduces asthma symptoms to extinction; decreases other medical needs; improves quality of life of the child; no side effect were distinguished.
Keywords: child asthma, pollen allergy, specific immunotherapy
Full text | PDF